286 related articles for article (PubMed ID: 22118788)
1. [Immunosuppressive treatment].
Niaudet P
Nephrol Ther; 2011 Dec; 7(7):592-8. PubMed ID: 22118788
[TBL] [Abstract][Full Text] [Related]
2. [Toward an evidence-based immunosuppression].
Pascual J
Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
[No Abstract] [Full Text] [Related]
3. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
4. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60.
Xenos EX; Ciancio G; Burke GW; Roth D; Miller J
Clin Transplant; 1997 Oct; 11(5 Pt 2):497-9. PubMed ID: 9361949
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppression for kidney transplant recipients: current strategies].
Alberú J; Urrea EM
Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
[TBL] [Abstract][Full Text] [Related]
6. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
7. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy.
Weber M; Deng S; Arenas J; Aradhye S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL
Transplant Proc; 1997 Dec; 29(8):3669-70. PubMed ID: 9414883
[No Abstract] [Full Text] [Related]
8. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
Weir MR
Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
[No Abstract] [Full Text] [Related]
9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
10. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan.
Mao PC; Lee EK; Tseng PL
Transplant Proc; 2012 Jan; 44(1):185-9. PubMed ID: 22310611
[TBL] [Abstract][Full Text] [Related]
11. What is the calcineurin inhibitor of choice for pediatric renal transplantation?
Kari JA; Trompeter RS
Pediatr Transplant; 2004 Oct; 8(5):437-44. PubMed ID: 15367278
[TBL] [Abstract][Full Text] [Related]
12. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
Tsai SF; Cheng CY; Shu KH; Wu MJ
Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients.
Gutiérrez Sánchez MJ; Morales Cerdán JM; Belmonte AA
Transplant Proc; 2009; 41(6):2320-2. PubMed ID: 19715907
[TBL] [Abstract][Full Text] [Related]
14. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients.
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2009 May; 119(5):318-25. PubMed ID: 19579814
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitor-free protocols: risks and benefits.
Barbari AG; Stephan AG; Masri MA
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):1-23. PubMed ID: 17237886
[TBL] [Abstract][Full Text] [Related]
18. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes.
Malinowski K; Ye H; Waltzer WC
Transplant Proc; 2000 Jun; 32(4):773-5. PubMed ID: 10856579
[No Abstract] [Full Text] [Related]
19. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
20. [Immunosuppressive treatments: mechanisms of action and clinical use].
Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
